Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis
Abstract Coagulation Factor XIa (FXIa) is an emerging target for antithrombotic agent development. The M358R variant of the serpin alpha-1 antitrypsin (AAT) inhibits both FXIa and other proteases. Our aim was to enhance the specificity of AAT M358R for FXIa. We randomized two AAT M358R phage display...
Guardado en:
Autores principales: | Varsha Bhakta, Mostafa Hamada, Amy Nouanesengsy, Jessica Lapierre, Darian L. Perruzza, William P. Sheffield |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4657582d6d9b43608bea58dc7f4701aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: David A. Donkor, et al.
Publicado: (2017) -
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Irina Petrache, et al.
Publicado: (2009) -
PROINFLAMMATORY CYTOKINE PROFILE IN PATIENTS WITH DIFFERENT ALPHA-1-ANTITRYPSIN PHENOTYPES
por: M. Yu. Pervakova, et al.
Publicado: (2016) -
Evaluation of Alpha-1 antitrypsin level in the serum of children with idiopathic bronchiectasis
por: Maryam Babaei, et al.
Publicado: (2021) -
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: Caitriona McLean, et al.
Publicado: (2009)